ATNX - アテネックス （Athenex Inc.） アテネックスATNXのチャート
ATNXの企業情報
| symbol | ATNx |
|---|---|
| 会社名 | Athenex Inc （アテネックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アテネックス(Athenex Inc.)は癌疾患および支持的療法向け治療法の開発および商品化に焦点を当てた腫瘍製薬会社である。同社の技術プラットフォームは経口吸収プラットフォーム、Srcキナーゼ阻害剤および症状治療薬の3つのカテゴリーに分類される。同社はパクリタキセルの経口製剤であるOraxol、イリノテカンの経口製剤であるOrateacan; オラドキセル、ドセタキセルの経口製剤、および各種タイプの癌治療用トポテカンの経口製剤を提供する。Srcキナーゼ阻害剤には、KX-01（KX2-391）およびKX-02（KX2-361）腫瘍薬候補が含まれる。同社の症状治療薬には、火傷や掻痒の治療用CQ-01、 照射誘発性皮膚炎の治療用CQ-R1、および化学療法誘発吐き気・嘔吐の治療用鼻腔内グラニセトロンを含む。 アテネックスは米国のバイオ医薬品企業。主にがん治療法の開発・商業化に従事する。同社製品の「Oraxol」は進行性胃がん治療用経口薬、「Oratecan」は大腸がん、肺がん、卵巣がん、子宮頸がん、膵臓がん治療の抗がん剤、「Oradoxel」は乳がん、前立腺がん、頭頸部がん、肺がん治療の抗がん剤などを含む。本社はニューヨーク州バッファロ―。 Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company's current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex's employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. |
| 本社所在地 | 1001 Main Street Suite 600 Buffalo NY 14203 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 716-898-8625 |
| 設立年月日 | 41244 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 477人 |
| url | www.athenex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/atnx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -84.80600 |
| 終値（lastsale） | 14.43 |
| 時価総額（marketcap） | 957329028.24 |
| 時価総額 | 時価総額（百万ドル） 945.38730 |
| 売上高 | 売上高（百万ドル） 78.26800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 866.22530 |
| 当期純利益 | 当期純利益（百万ドル） -61.51400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Athenex Inc revenues increased from $9.2M to $49.4M. Net loss decreased 45% to $44.2M. Revenues reflect Oncology Innovation Platform segment increase from $1M to $25.4M Commercial Platform segment increase from $1.9M to $15.7M United States segment increase from $2.9M to $17.8M Austria segment increase of 67% to $2.9M. |
ATNXのテクニカル分析
ATNXのニュース
Athenex Inc Shares Fall 4.8% Below Previous 52-Week Low - Market Mover 2021/09/30 11:46:57 iShook Finance
Athenex Inc (ATNX) shares closed 4.8% lower than its previous 52 week low, giving the company a market cap of $344M. The stock is currently down 71.5% year-to-date, down 74.3% over the past 12 months, and down 74.9% over the p
Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis 2021/09/27 12:00:00 Intrado Digital Media
Klisyri has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency and will initially be available for prescription in the UK and Germany
Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial 2021/09/16 12:04:15 Benzinga
Athenex Inc (NASDAQ: ATNX ) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab) in advanced solid malignancies. Paclitaxel is one of the most commonly used chemotherapies. Related Link: Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast … Full story available on Benzinga.com
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021 2021/09/16 06:30:00 Benzinga
BUFFALO, N.Y., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX ), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the presentation of data from a Phase 1 study to assess the safety, tolerability, and activity of oral paclitaxel and encequidar (Oral Paclitaxel) in combination with pembrolizumab in patients with advanced solid malignancies. The data are being presented in a poster presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 , being held from September 16 th to September 21 st . "The encouraging interim Phase 1 data suggest promising anti-cancer activity and expected safety and tolerability observations for oral paclitaxel with pembrolizumab in lung cancer patients who had progressed on PD1/PDL1 therapies," said Dr. Rudolf Kwan, Chief Medical Officer of Athenex. "PD1/PDL1 therapies are important treatments for lung cancer but most patients eventually progress, and those patients represent an area of high unmet medical need.
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts 2021/07/27 11:48:32 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Translate Bio, Inc. (NASDAQ: TBIO ) (moved on positive analyst action) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 26) 23andMe Holding Co. (NASDAQ: ME ) AbCellera Biologics Inc.
Athenex Inks Commercialization Pacts For Tirbanibulin In Australia, New Zealand 2021/07/26 14:02:24 Benzinga
Athenex Inc (NASDAQ: ATNX ) has entered into licensing agreements and partnerships with Seqirus Pty Ltd , a subsidiary of CSL Limited , and AVIR Pharma Inc to commercialize tirbanibulin. Under the terms of the agreements, Seqirus will have an exclusive license to Full story available on Benzinga.com
Athenex Announces Additional Licensing Agreements for Tirbanibulin 2021/07/26 11:00:00 Intrado Digital Media
Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada
U.S. Injectable Compounding Pharmacy Market Major Players Analysis - Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc. 2021/07/24 12:13:51 OpenPR
U.S. Injectable Compounding Pharmacy Market Report 2021 added recently by CMI, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities
Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast Cancer 2021/07/06 13:20:38 Benzinga
Athenex Inc (NASDAQ: ATNX ) held a Type A meeting with the FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter (CRL) regarding application for Full story available on Benzinga.com
Athenex FDA Encequidar A 2021/07/06 11:00:00 Intrado Digital Media
, July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) 2021 (FDA) A 2
SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders 2021/06/07 18:57:00 Business Wire
SAN DIEGO & BUFFALO, N.Y.--(BUSINESS WIRE)---- $ATNX #ATNX--Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Athenex is a global clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next generation drugs for the treatment of cancer. One of the Company''s main drug can
Oppenheimer Maintains Their Hold Rating on Athenex (ATNX) 2021/06/07 11:15:29 Smarter Analyst
Oppenheimer analyst Kevin DeGeeter maintained a Hold rating on Athenex (ATNX) today. The companys shares closed last Friday at $4. The post Oppenheimer Maintains Their Hold Rating on Athenex (ATNX) appeared first on Smarter Analyst .